Literature DB >> 7246599

Severe leukopenia and mild thrombocytopenia after chronic bromocriptine (CB-154) administration.

O Giampietro, M Ferdeghini, M Petrini.   

Abstract

A 23-year-old woman was receiving bromocriptine (CB-154, 7.5-10 mg/day, for a hyperprolactinemic galactorrhea-amenorrhea syndrome. She also had insulin-dependent diabetes. After three months the bromocriptine therapy was stopped because she developed severe leukopenia (leukocyte counts about 1,800/cu mm) and mild thrombocytopenia (platelet count about 130,000/cu mm). Five months after stopping the bromocriptine therapy, the leukocyte count returned to normal (4,400/cu mm), as did the platelet count (238,000/cu mm). Prior to bromocriptine therapy, the patient's leukocyte and platelet counts ranged between 5,500 and 6,000/cu mm and 250,000 and 300,000/cu mm, respectively. While taking bromocriptine she was on insulin maintenance therapy and took no other drugs. Regular menses had returned and spontaneous galactorrhea had disappeared during bromocriptine therapy, and serum prolactin levels became normal. After stopping bromocriptine therapy the patient again became basally hyperprolactinemic and amenorrheic, with spontaneous galactorrhea. The article discusses possible mechanisms of this hematologic reaction.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7246599     DOI: 10.1097/00000441-198105000-00008

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  3 in total

Review 1.  A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors:  J Webster
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

2.  Teratogenicity of bromocryptine in pregnant rats.

Authors:  D Weinstein; D Ben-Amitay; J G Schenker; A Ornoy; A A Hochberg; R Folman
Journal:  Arch Gynecol       Date:  1982

3.  Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Authors:  Fabio Giuseppe Liberante; Tara Pouryahya; Mary-Frances McMullin; Shu-Dong Zhang; Kenneth Ian Mills
Journal:  Oncotarget       Date:  2016-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.